Bayer HealthCare and partner Onyx Pharmaceuticals have unveiled new clinical trial data showing the potential of Nexavar tablets to treat a certain form of cancer.
Results from the phase III Decision study demonstrated that Nexavar delivered progression-free survival benefits among patients with locally advanced or metastatic radioactive iodine (RAI)-refractory differentiated thyroid cancer.
“Bayer HealthCare and Onyx Pharmaceuticals have reported clinical trial data showing the efficacy of Nexavar in the treatment of certain forms of thyroid cancer.“
The safety and tolerability profiles of the drug were also shown to be positive, suggesting Nexavar could be an effective therapy for a condition for which there are currently limited options available.
Bayer plans to submit the Decision data to support marketing authorisation applications for Nexavar in the treatment of RAI-refractory differentiated thyroid cancer.
Dr Dimitris Voliotis, vice-president for global clinical oncology development at Bayer HealthCare, said: "We are pleased that the results of this study demonstrate that Nexavar may provide a treatment option for these patients."
This comes after the firm submitted radium-223 dichloride for European approval in the treatment of castration-resistant prostate cancer last month.